Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
44
SNSE Quote, Financials, Valuation and Earnings
Last price:
$0.44
Seasonality move
:
1.19%
Day range:
$0.42 - $0.47
52-week range:
$0.38 - $1.94
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.25x
Volume:
272.4K
Avg. volume:
372.2K
1-year change:
-28.02%
Market cap:
$11.3M
Revenue:
--
EPS (TTM):
-$1.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SNSE
Sensei Biotherapeutics
|
-- | -$0.32 | -- | -- | -- |
|
ENSC
Ensysce Biosciences
|
$200K | -$5.25 | -- | -90.51% | -- |
|
GNPX
Genprex
|
-- | -$2.73 | -- | -89.71% | -- |
|
INAB
IN8bio
|
-- | -$0.16 | -- | -55.56% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$2.6M | -$0.31 | -60.77% | -99.16% | -- |
|
RLMD
Relmada Therapeutics
|
-- | -- | -- | -- | $10.88 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SNSE
Sensei Biotherapeutics
|
$0.45 | -- | $11.3M | -- | $0.00 | 0% | -- |
|
ENSC
Ensysce Biosciences
|
$8.03 | -- | $10.5M | -- | $0.00 | 0% | -- |
|
GNPX
Genprex
|
$0.91 | -- | $7.7M | -- | $0.00 | 0% | -- |
|
INAB
IN8bio
|
$0.25 | -- | $18M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.53 | -- | $2.6M | -- | $0.00 | 0% | 0.06x |
|
RLMD
Relmada Therapeutics
|
$0.36 | $10.88 | $11M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SNSE
Sensei Biotherapeutics
|
-- | 0.541 | -- | -- |
|
ENSC
Ensysce Biosciences
|
-- | -6.072 | -- | -- |
|
GNPX
Genprex
|
-- | -20.874 | -- | -- |
|
INAB
IN8bio
|
-- | 2.705 | -- | -- |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.704 | 1.51% | 0.75x |
|
RLMD
Relmada Therapeutics
|
-- | 3.172 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SNSE
Sensei Biotherapeutics
|
-- | -$7.8M | -- | -- | -- | -$5.5M |
|
ENSC
Ensysce Biosciences
|
-- | $644.8K | -- | -- | -- | -$1M |
|
GNPX
Genprex
|
-- | -$4.3M | -- | -- | -- | -$2.2M |
|
INAB
IN8bio
|
-- | -$6M | -- | -- | -- | -$6.1M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
RLMD
Relmada Therapeutics
|
-- | -$23M | -- | -- | -- | -$16.7M |
Sensei Biotherapeutics vs. Competitors
-
Which has Higher Returns SNSE or ENSC?
Ensysce Biosciences has a net margin of -- compared to Sensei Biotherapeutics's net margin of --. Sensei Biotherapeutics's return on equity of -- beat Ensysce Biosciences's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SNSESensei Biotherapeutics-- -$0.29 -- ENSCEnsysce Biosciences-- $1.05 -- -
What do Analysts Say About SNSE or ENSC?
Sensei Biotherapeutics has a consensus price target of --, signalling upside risk potential of 816.87%. On the other hand Ensysce Biosciences has an analysts' consensus of -- which suggests that it could grow by 1170.24%. Given that Ensysce Biosciences has higher upside potential than Sensei Biotherapeutics, analysts believe Ensysce Biosciences is more attractive than Sensei Biotherapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SNSESensei Biotherapeutics0 0 0 ENSCEnsysce Biosciences0 0 0 -
Is SNSE or ENSC More Risky?
Sensei Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ensysce Biosciences has a beta of 0.598, suggesting its less volatile than the S&P 500 by 40.229%.
-
Which is a Better Dividend Stock SNSE or ENSC?
Sensei Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ensysce Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensei Biotherapeutics pays -- of its earnings as a dividend. Ensysce Biosciences pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNSE or ENSC?
Sensei Biotherapeutics quarterly revenues are --, which are smaller than Ensysce Biosciences quarterly revenues of --. Sensei Biotherapeutics's net income of -$7.3M is lower than Ensysce Biosciences's net income of $661.8K. Notably, Sensei Biotherapeutics's price-to-earnings ratio is -- while Ensysce Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensei Biotherapeutics is -- versus -- for Ensysce Biosciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNSESensei Biotherapeutics-- -- -- -$7.3M ENSCEnsysce Biosciences-- -- -- $661.8K
-
Which has Higher Returns SNSE or GNPX?
Genprex has a net margin of -- compared to Sensei Biotherapeutics's net margin of --. Sensei Biotherapeutics's return on equity of -- beat Genprex's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SNSESensei Biotherapeutics-- -$0.29 -- GNPXGenprex-- -$1.23 -- -
What do Analysts Say About SNSE or GNPX?
Sensei Biotherapeutics has a consensus price target of --, signalling upside risk potential of 816.87%. On the other hand Genprex has an analysts' consensus of -- which suggests that it could grow by 724.18%. Given that Sensei Biotherapeutics has higher upside potential than Genprex, analysts believe Sensei Biotherapeutics is more attractive than Genprex.
Company Buy Ratings Hold Ratings Sell Ratings SNSESensei Biotherapeutics0 0 0 GNPXGenprex0 0 0 -
Is SNSE or GNPX More Risky?
Sensei Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Genprex has a beta of -1.377, suggesting its less volatile than the S&P 500 by 237.675%.
-
Which is a Better Dividend Stock SNSE or GNPX?
Sensei Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genprex offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensei Biotherapeutics pays -- of its earnings as a dividend. Genprex pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNSE or GNPX?
Sensei Biotherapeutics quarterly revenues are --, which are smaller than Genprex quarterly revenues of --. Sensei Biotherapeutics's net income of -$7.3M is lower than Genprex's net income of -$4.3M. Notably, Sensei Biotherapeutics's price-to-earnings ratio is -- while Genprex's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensei Biotherapeutics is -- versus -- for Genprex. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNSESensei Biotherapeutics-- -- -- -$7.3M GNPXGenprex-- -- -- -$4.3M
-
Which has Higher Returns SNSE or INAB?
IN8bio has a net margin of -- compared to Sensei Biotherapeutics's net margin of --. Sensei Biotherapeutics's return on equity of -- beat IN8bio's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SNSESensei Biotherapeutics-- -$0.29 -- INABIN8bio-- -$0.15 -- -
What do Analysts Say About SNSE or INAB?
Sensei Biotherapeutics has a consensus price target of --, signalling upside risk potential of 816.87%. On the other hand IN8bio has an analysts' consensus of -- which suggests that it could grow by 1809.16%. Given that IN8bio has higher upside potential than Sensei Biotherapeutics, analysts believe IN8bio is more attractive than Sensei Biotherapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SNSESensei Biotherapeutics0 0 0 INABIN8bio2 0 0 -
Is SNSE or INAB More Risky?
Sensei Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IN8bio has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SNSE or INAB?
Sensei Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IN8bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensei Biotherapeutics pays -- of its earnings as a dividend. IN8bio pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNSE or INAB?
Sensei Biotherapeutics quarterly revenues are --, which are smaller than IN8bio quarterly revenues of --. Sensei Biotherapeutics's net income of -$7.3M is lower than IN8bio's net income of -$7.1M. Notably, Sensei Biotherapeutics's price-to-earnings ratio is -- while IN8bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensei Biotherapeutics is -- versus -- for IN8bio. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNSESensei Biotherapeutics-- -- -- -$7.3M INABIN8bio-- -- -- -$7.1M
-
Which has Higher Returns SNSE or NBY?
NovaBay Pharmaceuticals has a net margin of -- compared to Sensei Biotherapeutics's net margin of -49.65%. Sensei Biotherapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital SNSESensei Biotherapeutics-- -$0.29 -- NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About SNSE or NBY?
Sensei Biotherapeutics has a consensus price target of --, signalling upside risk potential of 816.87%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that Sensei Biotherapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Sensei Biotherapeutics is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings SNSESensei Biotherapeutics0 0 0 NBYNovaBay Pharmaceuticals0 0 0 -
Is SNSE or NBY More Risky?
Sensei Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.
-
Which is a Better Dividend Stock SNSE or NBY?
Sensei Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensei Biotherapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNSE or NBY?
Sensei Biotherapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Sensei Biotherapeutics's net income of -$7.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Sensei Biotherapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensei Biotherapeutics is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNSESensei Biotherapeutics-- -- -- -$7.3M NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M
-
Which has Higher Returns SNSE or RLMD?
Relmada Therapeutics has a net margin of -- compared to Sensei Biotherapeutics's net margin of --. Sensei Biotherapeutics's return on equity of -- beat Relmada Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SNSESensei Biotherapeutics-- -$0.29 -- RLMDRelmada Therapeutics-- -$0.72 -- -
What do Analysts Say About SNSE or RLMD?
Sensei Biotherapeutics has a consensus price target of --, signalling upside risk potential of 816.87%. On the other hand Relmada Therapeutics has an analysts' consensus of $10.88 which suggests that it could grow by 138.69%. Given that Sensei Biotherapeutics has higher upside potential than Relmada Therapeutics, analysts believe Sensei Biotherapeutics is more attractive than Relmada Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SNSESensei Biotherapeutics0 0 0 RLMDRelmada Therapeutics2 3 0 -
Is SNSE or RLMD More Risky?
Sensei Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Relmada Therapeutics has a beta of 0.353, suggesting its less volatile than the S&P 500 by 64.671%.
-
Which is a Better Dividend Stock SNSE or RLMD?
Sensei Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Relmada Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensei Biotherapeutics pays -- of its earnings as a dividend. Relmada Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNSE or RLMD?
Sensei Biotherapeutics quarterly revenues are --, which are smaller than Relmada Therapeutics quarterly revenues of --. Sensei Biotherapeutics's net income of -$7.3M is higher than Relmada Therapeutics's net income of -$21.7M. Notably, Sensei Biotherapeutics's price-to-earnings ratio is -- while Relmada Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensei Biotherapeutics is -- versus -- for Relmada Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNSESensei Biotherapeutics-- -- -- -$7.3M RLMDRelmada Therapeutics-- -- -- -$21.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
